Cell sources of advanced-therapy medicinal products (ATMPs)

Márton Varju, Bovenberg Jasper, Judit Sándor

Research output: Contribution to Book/Report typesChapterpeer-review

Abstract (may include machine translation)

In Work Package 2, our aim was to answer to the following questions: what 18
are the interactions between EU and national legislation and the procurement
of human (embryonic, foetal, and adult) stem cells for research, innovation
and therapy and what are the effects of the application and implementation
of that legislation on human stem cell procurement. Our main research
methods included legal and comparative legal analysis which were applied
in an empirical setting reflecting on the scientific and technological state of
play in the domain. Our work was carried out with the specific end in mind
of informing the Commission of the legal evidence basis that will enable the
improvement and the optimisation of the innovative potential, the efficacy
and efficiency, and the ethical soundness of future legislation in this area of
biomedical research and innovation
Original languageEnglish
Title of host publicationGoverning Stem cells. Regenerative medicine in Europe
Place of PublicationToulouse
PublisherInstitut National de la Santé et de la Recherche Medicale (INSERM)
Pages17-34
Number of pages18
ISBN (Print)9782855989099
StatePublished - 2018

Fingerprint

Dive into the research topics of 'Cell sources of advanced-therapy medicinal products (ATMPs)'. Together they form a unique fingerprint.

Cite this